Strategy “treat to target” for patients with psoriasis. Relevant issues to biological therapy persistence

Cover Page

Cite item


The review discusses the possibility of result-oriented treatment therapeutic strategy (Т2Т) for patients with psoriasis implementation, as well as analysis of the key factors to ensure stability of long-term therapy with the use of genetically engineered biological drugs. It contains data on targeted influence of inhibitor IL17A secukinumab on key factors in the immunopathogenesis of psoriasis, its efficiency and safety in treating patients with moderately-severe to severe psoriasis in the course of therapy lasting up to 3 years. It is shown that long-term usage of secukinumab with 300 mg dose once a month subcutaneously allows to reduce the severity index values and the prevalence of psoriasis PASI 90% to vast number of patients with this dermatosis, which fully corresponds to the T2T strategy. The review discusses the possibility of therapeutic response usage in the form of achieving PASI 90 as a new global goal for effective therapy for patients with psoriasis to be attained in clinical practice. We present data on immunogenicity profile of secukinumab and beneficial impact on efficiency, as well as on safety of treatment with the usage of this genetically engineered biological medication.

About the authors

A. L. Bakulev

Saratov State Medical University named after V.I. Razumovsky

Author for correspondence.
Russian Federation


  1. Smolen J., Alehata D., Biijsma J.W. At al. Nreating rheumatoid arthritis to target: recommendations of an international task forse. Ann Rheum Dis 2010 Apr; 69 (4): 631-7.
  2. Nast A., Boehncke W.-H., Mrowietz U. et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012; 10 (Suppl. 2): S1-95.
  3. Menter А., Korman N.J., Elmets C.A. et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2011; 65: 137-74.
  4. Federalnyye klinicheskiye rekomendatsii po vedeniyu bolnykh psoriazom. Rossiyskoye obshchestvo dermatovenerologov i kosmetologov. M. 2015.
  5. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009 Aug 27; 361 (9): 888-98.
  6. Ivanov S., Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009 Feb; 30 (2): 95-103.
  7. Kolls J., Linden A. Immunity 2004; 21: 467-476.
  8. Gaffen S. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9: 556-567.
  9. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008; 19: 41-52.
  10. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu Rev Immunol 2007; 25: 821-852.
  11. Puel A., Cypowyi S., Bustamante J et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011; 332: 65-68.
  12. Bovenschen H.J., Van de Kerkhof P.C., Van Erp P.E. et al. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin Journal of Investigative Dermatology (2011) 131, 1853-1860.
  13. Nestle F., Kaplan D.H., Barcer J. Psoriasis. N Engl J Med 2009; 361: 496-509.
  14. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485-517.
  15. Onishi R., Gaffen S. Immunology 2010; 129: 311-32.
  16. Langley R.G., Elewski B.E., Lebwohl M. et al. Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials. N Engl J Med 2014; 371: 326-338.
  17. Mrowietz U., Leonardi C.L., Girolomoni G. et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol 2015 Jul; 73 (1): 27-36.
  18. Schafer I., Hacker J., Rustenbach S.J. et al. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010; 20 (1): 62-67.
  19. Armstrong A.W., Robertson A.D., Wu J. et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol 2013; 149 (10): 1180-1185.
  20. Breedveld F.C. Therapeutic monoclonal antibodies. Lancet 2000 Feb 26; 355 (9205): 735-40.
  21. Hsu L., Snodgrass B.T., Armstrong A.W. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol (2014): 170; 261-273.
  22. Kozentiks (sekukinumab). Instruktsiya po primeneniyu lekarstvennogo preparata. Moskva. 2016. [козентикс (секукинумаб). Инструкция по применению лекарственного препарата. М, 2016.]
  23. FDA center for drug evaluation and research application number: 1255040rig1s000; http:// nda/2015/1255040rig1s000MedR.pdf
  24. Novartis Data on File. Obobshchennyye dannyye po bezopasnosti pri psoriaze. 2015. [Novartis Data on File. Обобщенные данные по безопасности при псориазе, 2015.]
  25. Hernandez-Santos N., Gaffen S.L.Th17 cells in immunity to Candida albicans. Cell Host Microbe 2012 May 17; 11 (5): 425-35.
  26. Hernandez-Santos N., Huppler A.R., Peterson A.C. et al. Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections. Mucosal Immunol 2013 Sep; 6 (5): 900-10.

Copyright (c) 2016 Bakulev A.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies